Rational drug design and HIV: Hopes and limitations

1. Abdel-Meguid, S.S. Inhibitors of aspartyl proteinases. Med. Res. Rev. 13, 731−778 (1993). | PubMed  | ChemPort |
2. Pauwels, R. et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343, 470−474 (1990). | Article | PubMed  | ISI | ChemPort |
3. Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. & Steitz, T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783−1790 (1992). | PubMed  | ISI | ChemPort |
4. Jacobo-Molina, A. et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. natn. Acad. Sci. U.S.A. 90, 6320−6324 (1993). | ChemPort |
5. Smerdon, S.J. et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. natn. Acad. Sci. U.S.A. 91, 3911−3915 (1994). | ChemPort |
6. Ding, J. et al. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor -APA R 95845 at 2.8 Å resolution. Structure 3 365−379 (1995). | PubMed  | ISI | ChemPort |
7. Ren, J.S. et al. High resolution structure of HIV-1 RT: Insights from four RT-inhibitor complexes. Nature struct. Biol. 2 293−302 (1995). | PubMed  | ISI | ChemPort |
8. Esnouf, R. et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature struct. Biol. 2 303−308 (1995). | PubMed  | ISI | ChemPort |
9. Rodgers, D.W. et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. natn. Acad. Sci. U.S.A. 92 1222−1226 (1995). | ChemPort |
10. Spence, R.A., Kati, W.M., Anderson, K.S. & Johnson, K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267 988−993 (1995). | PubMed  | ISI | ChemPort |
11. Rittinger, K., Divita, G., Muller, B. & Goody, R.S. HIV reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by non-nucleoside inhibitors. Proc. natn. Acad. Sci. U.S.A. (in the press).
12. Collins, J.R., Burt, S.K. & Erickson, J.W. Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics. Nature struct. Biol. 2 334−338 (1995). | PubMed  | ISI | ChemPort |
13. Caspar, D. Problems in simulating macromolecular movements. Structure 3 327−329 (1995). | PubMed  | ISI | ChemPort |
14. Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569−571 (1995). | Article | PubMed  | ISI | ChemPort |
15. Tisdale, M., Kemp, S.D., Parry, N.R. & Larder, B.A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. natn. Acad. Sci. U.S.A. 90, 5653−5656 (1993). | ChemPort |
16. Divita, G., Restle, T., Goody, R.S., Chermann, J.-C. & Baillon, J.G. Inhibition of human immunodeficiency virus type I reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J. biol. Chem. 269, 13080−13083 (1994). | PubMed  | ISI | ChemPort |
17. Liuzzi, M. et al. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372, 695−698 (1994). | Article | PubMed  | ISI | ChemPort |
18. Bushman, F. Targeting retroviral integration. Science 267 1443−1444 (1995) | PubMed  | ISI | ChemPort |
19. Lasic, D.D. & Papahadjopulos, D. Liposomes revisited. Science 267 1275−1276 (1995). | PubMed  | ISI | ChemPort |

	Top

	Top